表紙
市場調査レポート

KunWha Pharmaceutical Co., Ltd.:製品パイプライン分析

KunWha Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 306088
出版日 ページ情報 英文 28 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
KunWha Pharmaceutical Co., Ltd.:製品パイプライン分析 KunWha Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014
出版日: 2014年06月15日 ページ情報: 英文 28 Pages
概要

KunWha Pharmaceutical Co., Ltd.は、様々な治療領域の処方薬を製造する製薬企業です。

当レポートでは、KunWha Pharmaceutical Co., Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

KunWha Pharmaceutical Co., Ltd.の基本情報

KunWha Pharmaceutical Co., Ltd.の概要

  • 主要情報
  • 企業情報

KunWha Pharmaceutical Co., Ltd.:R&Dの概要

  • 主な治療範囲

KunWha Pharmaceutical Co., Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

KunWha Pharmaceutical Co., Ltd.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

KunWha Pharmaceutical Co., Ltd.:薬剤プロファイル

  • fentanyl citrate
  • pregabalin ER
  • sarpogrelate SR
  • KW-21072
  • KW-21097

KunWha Pharmaceutical Co., Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

KunWha Pharmaceutical Co., Ltd.:最近のパイプライン動向

KunWha Pharmaceutical Co., Ltd.:本社と子会社の所在地

付録

目次
Product Code: GMDHC05014CDB

Global Markets Direct's, 'KunWha Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the KunWha Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of KunWha Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of KunWha Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of KunWha Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the KunWha Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate KunWha Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of KunWha Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the KunWha Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of KunWha Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of KunWha Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of KunWha Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • KunWha Pharmaceutical Co., Ltd. Snapshot
    • KunWha Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • KunWha Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • KunWha Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • KunWha Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • KunWha Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • KunWha Pharmaceutical Co., Ltd. - Drug Profiles
    • fentanyl citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pregabalin ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sarpogrelate SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KW-21072
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KW-21097
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Analysis
    • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • KunWha Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • KunWha Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • KunWha Pharmaceutical Co., Ltd., Key Information
  • KunWha Pharmaceutical Co., Ltd., Key Facts
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • KunWha Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • KunWha Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014
  • KunWha Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pre-Registration, 2014
  • KunWha Pharmaceutical Co., Ltd. - Phase III, 2014
  • KunWha Pharmaceutical Co., Ltd. - Phase I, 2014
  • KunWha Pharmaceutical Co., Ltd. - Discovery, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Target, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
  • KunWha Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014
  • KunWha Pharmaceutical Co., Ltd., Other Locations

List of Figures

  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • KunWha Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • KunWha Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top